EUCTR2021-006870-22-AT进行中（未招募）1 期
Substitution of coagulation factors and blood products in patients with liver cirrhosis - COUCH - Coagulation in Cirrhosis
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- liver cirrhosis
- •- elective micro wave ablation, radio frequency ablation, biopsy/puncture of the liver (percutaneous or transjugular), percutaneous transhepatic cholangiodrainage, transjugular intrahepatic portosystemic shunt
- •- INR > 1,5 and/or PLT count < 50 G/L
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- age < 18 years
- •- patients unable to consent
- •- clinical signs or history of bleeding
- •- chronic kidney disease stage G4 or G5 according to KDIGO
- •- relevant ascites
- •- pregnant or breast feeding women
- •- not paused anticoagulant medication (except acteylsalicylic acid)
研究者
相似试验
已完成
不适用
Evaluation of Hemostatics in coagulation inhibited human blood with viscoelastic testing (ROTEM)R58D68.9Haemorrhage, not elsewhere classifiedCoagulation defect, unspecifiedDRKS00015034Bundeswehrkrankenhaus UlmKlinik für Anästhesie und IntensivmedizinSektion Notfallmedizin40
招募中
不适用
The elucidation of the coagulation and fibrinolysis system in a cancer patients, and search of a biomarkerEsophageal cancer, Gynecological cancer, Lung cancerJPRN-UMIN000035432Hoshigaoka Medical Cennter600
进行中（未招募）
不适用
?Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF?PFM): A Phase 3/4, prospective, controlled, randomized, multi-center Study to compare the efficacy and safety of continous infusion (CI) versus intermittent bolus infusion (BI) in subjects With Severe Or Moderately Severe Hemophilia A undergoing unilateral primary total knee replacement? - Advate Randomized Surgery StudyPatients suffering from severe to moderately severe Haemophilia A (basal level of factor VIII < 2% of normal) undergoing Primary Total Unilateral Substitution of the Knee.MedDRA version: 9.1Level: LLTClassification code 10061992Term: HaemophiliaEUCTR2005-005697-71-ITBaxter Innovations GmbH60
进行中（未招募）
1 期
The main goal of the study is to compare the safety and effectiveness of administering ADVATE using either continuous infusion or single, large dose infusions during and post surgery for patients requiring major orthopedic surgeryEUCTR2005-005697-71-SEBaxter Innovations GmbH21
进行中（未招募）
不适用
The main goal of the study is to compare the safety and effectiveness of administering ADVATE using either continuous infusion or single, large dose infusions during and post surgery for patients requiring major orthopedic surgeryEUCTR2005-005697-71-PLBaxalta Innovations GmbH21